GlassScriptPhysician profile
George J Antalis
NPI 1013938877
$3,395.82
in general payments reported to CMS, 2019-2025
27 companies · $688 in 2025
The $688 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $119 · 2021: $317 · 2022: $168 · 2023: $272 · 2024: $1,040 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,999.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $642.25 | 2024-2025 | Resolute Onyx, Symplicity G3, Complete Se Vascular |
| Novartis Pharmaceuticals Corporation | $392.52 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $306.28 | 2019-2024 | Xarelto |
| Amgen INC. | $268.52 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $260.82 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $215.01 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.21 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $137.49 | 2019-2025 | Wainua, Farxiga |
| Abbott Laboratories | $114.50 | 2021-2023 | Jot Dx |
| Shockwave Medical, INC | $110.85 | 2021 | |
| Merck Sharp & Dohme LLC | $83.91 | 2021-2023 | Verquvo |
| Amarin Pharma, INC. | $80.88 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.21 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $75.26 | 2019-2023 | |
| Heartflow, INC. | $63.93 | 2022-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $52.77 | 2025 | |
| Boston Scientific Corporation | $45.46 | 2019-2025 | Cds - Mct/Cem Monitoring |
| Regeneron Healthcare Solutions, INC. | $38.71 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $36.93 | 2024 | Arcalyst |
| Philips North America LLC | $35.45 | 2024 | (Ck4) Mcot, (P77) Azurion 7 M20 |
| Recor Medical INC | $33.28 | 2025 | Paradise Ultrasound Renal Denervation System |
| Irhythm Technologies, INC. | $30.94 | 2024 | Zio Monitor, Zio Xt Patch |
| Kestra Medical Technology Services, INC. | $30.64 | 2022 | |
| Inspire Medical Systems, INC. | $27.62 | 2024 | Inspire |
| Abiomed | $25.15 | 2024 | Impella |
| Xeris Pharmaceuticals, INC. | $24.44 | 2025 | Keveyis |
| Kowa Pharmaceuticals America, INC. | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Antalis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.